6622 Stock Overview
An ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Zhaoke Ophthalmology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.79 |
| 52 Week High | HK$1.88 |
| 52 Week Low | HK$1.20 |
| Beta | 1.06 |
| 1 Month Change | 27.86% |
| 3 Month Change | 32.59% |
| 1 Year Change | 5.29% |
| 3 Year Change | -61.91% |
| 5 Year Change | n/a |
| Change since IPO | -87.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6622 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0.6% | 6.1% | 2.6% |
| 1Y | 5.3% | 4.8% | 25.9% |
Return vs Industry: 6622 matched the Hong Kong Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: 6622 underperformed the Hong Kong Market which returned 26.2% over the past year.
Price Volatility
| 6622 volatility | |
|---|---|
| 6622 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.9% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 6622 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6622's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 297 | Benjamin Li | www.zkoph.com |
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong. It is developing various drugs that cover ophthalmic indications, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited.
Zhaoke Ophthalmology Limited Fundamentals Summary
| 6622 fundamental statistics | |
|---|---|
| Market cap | HK$977.59m |
| Earnings (TTM) | -HK$243.29m |
| Revenue (TTM) | HK$61.31m |
15.9x
P/S Ratio-4.0x
P/E RatioIs 6622 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6622 income statement (TTM) | |
|---|---|
| Revenue | CN¥57.22m |
| Cost of Revenue | CN¥10.28m |
| Gross Profit | CN¥46.93m |
| Other Expenses | CN¥274.00m |
| Earnings | -CN¥227.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 82.03% |
| Net Profit Margin | -396.86% |
| Debt/Equity Ratio | 11.0% |
How did 6622 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 06:58 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhaoke Ophthalmology Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| Yue-Kwong Lui | Jefferies LLC |